Several listed medical companies are channeling hundreds of millions of yuan into funds by becoming Limited Partners (LPs), thereby venturing into the realms of artificial intelligence (AI) and semiconductors, with the strategic intent of reaping cross-industry benefits. Notably, Jiuan Medical has adeptly capitalized on AI opportunities through targeted technology innovation investments, leading to substantial profit growth. The company has pioneered a dual-wheel-driven model, combining its 'core medical business with technology innovation investment,' thereby setting a precedent for peers such as Yuyue Medical and Mingde Biotech. This move has inspired these companies to also explore布局 (strategically position themselves) in emerging sectors.

Each company adopts distinct strategies: some forge alliances with semiconductor industry leaders to safeguard supply chain stability and construct a health management ecosystem; others harness their abundant financial resources to invest in cutting-edge technologies; certain firms make significant AI investments, leveraging the technological acumen of the second generation of their founding families; and yet others, when faced with slowing growth in their core businesses, seek new avenues for returns through strategic investments. Such cross-industry investments are not mere trend-following endeavors but are driven by a strategic vision to acquire technological entry points via capital, foster the integration of AI with their existing operations, and propel product enhancements and operational efficiency gains.

However, it is worth noting that the majority of listed medical companies still opt to concentrate their investments within the vertical medical sector, reflecting a cautious yet focused approach to capital allocation.